Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Completed · Phase 2

Conditions studied: Recurrent Platinum Resistant Ovarian Cancer

In brief

This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.

Key facts

Study ID: NCT02889900
Run by: AstraZeneca
People needed: 62
Starts: 2017-01-17
Expected to finish: 2021-03-16
Last updated by the study team: 2022-03-08

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Ability and willingness to provide written informed consent, and to comply with the requirements of the protocol
Females aged ≥18 years with previous histologically proven diagnosis of high grade serous, high grade endometroid or clear cell ovarian cancer, fallopian tube or primary peritoneal carcinoma
No evidence of deleterious or suspected deleterious germline mutation in BRCA1 or BRCA2 genes
Recurrent platinum-resistant disease, defined as disease progression within 6 months (182 days) of the last receipt of platinum-based chemotherapy
CT/MRI evidence of measurable disease as per RECIST 1.1 defined as at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) and which is suitable for accurate repeated measurements
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Life expectancy ≥12 weeks
Prior receipt of antiangiogenic treatment, including but not limited to bevacizumab, is optional. If used, it can be used in the first line or recurrent setting.
At least three prior lines of therapy for advanced ovarian cancer as defined in the protocol
Confirmation of the availability of a tumor sample from the primary or recurrent cancer must be provided
Patients must have adequate organ and bone marrow function
Adequately controlled blood pressure
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction
Able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of IPs

You may not qualify if…

Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Previous enrollment in the present study.
Exposure to any IP during the last 4 weeks prior to enrollment.
Previous treatment with PARP inhibitor. For this study, BSI-201 (iniparib) is not considered as PARPi
Recent cancer-directed therapies: Radiotherapy (RT) within 4 weeks, chemotherapy or other systemic anti-cancer therapy within 4 weeks, or prior anti-angiogenic treatment (e.g., bevacizumab) within 6 weeks prior to starting treatment
Cancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable disease
Major surgical procedure within 2 weeks prior to starting treatment; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
Clinically significant signs and/or symptoms of bowel obstruction within 3 months prior to starting treatment
History of intra-abdominal abscess within 3 months prior to starting treatment
History of GI perforation. Patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired, there has been no evidence of fistula for at least 6 months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula
Other malignancy within the last 5 years
Persisting ≥Grade 2 CTCAE toxicity (except alopecia and Grade 2 peripheral neuropathy) from previous anti-cancer treatment(s)
Central nervous system metastases
Patients with any of the following: History of myocardial infarction within 6 months prior to starting treatment; Unstable angina; Resting electrocardiogram (ECG) with clinically significant abnormal findings; New York Heart Association functional classification of III or IV
Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN) per institutional guidelines, or <55%, if threshold for normal not otherwise specified by institutional guidelines, for patients with the following risk factors: Prior treatment with anthracyclines; Prior treatment with trastuzumab; Prior central thoracic RT, including exposure of heart to therapeutic doses of ionizing RT; History of myocardial infarction within 6-12 months prior to start of IPs; Prior history of other significant impaired cardiac function
History of stroke or transient ischemic attack within 6 months
Uncontrolled intercurrent illness
Patients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
No prior allogenic bone marrow transplant or double umbilical cord blood transplantation
Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatment
Concomitant use of known strong or moderate CYP3A inhibitors
Concomitant use of known strong or moderate CYP3A inducers

Where it is running

Research Site — Mobile, Alabama, United States
Research Site — Anchorage, Alaska, United States
Research Site — Downey, California, United States
Research Site — Greenbrae, California, United States
Research Site — Orange, California, United States
Research Site — San Diego, California, United States
Research Site — San Francisco, California, United States
Research Site — West Hollywood, California, United States
Research Site — Miami, Florida, United States
Research Site — Miami, Florida, United States
Research Site — Orlando, Florida, United States
Research Site — Augusta, Georgia, United States
Research Site — Newnan, Georgia, United States
Research Site — Fort Wayne, Indiana, United States
Research Site — Westwood, Kansas, United States
Research Site — Covington, Louisiana, United States
Research Site — Towson, Maryland, United States
Research Site — Boston, Massachusetts, United States
Research Site — Billings, Montana, United States
Research Site — New York, New York, United States
Research Site — Rochester, New York, United States
Research Site — Charlotte, North Carolina, United States
Research Site — Winston-Salem, North Carolina, United States
Research Site — Knoxville, Tennessee, United States
Research Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.